PFDA in the Bedroom

At a glance

What it is

PFDA — perfluorodecanoic acid, CAS 335-76-2 — is the 10-carbon perfluoroalkyl carboxylic acid. Structurally, PFDA parallels PFOA except for two additional perfluorinated carbons (C10 vs C8). The chemistry that defines PFDA as a PFAS is the same as for every PFAS: fully fluorinated perfluoroalkyl chain with C–F bonds that resist environmental degradation on any human-relevant timescale. The longer chain produces predictable toxicokinetic and environmental fate differences from shorter-chain carboxylates: longer half-life in humans, higher bioaccumulation in aquatic organisms, stronger adsorption to soil and sediment.

The PFDA commercial story largely tracks the broader long-chain PFAS story. Long-chain perfluoroalkyl carboxylates including PFDA were widely used in fluoropolymer manufacturing, paper food-contact coatings, textile water-repellent treatments, and certain firefighting foam formulations through the late 2000s. The 2006 EPA PFOA Stewardship Program — a voluntary agreement with 3M, DuPont, Daikin, and other major fluorochemical manufacturers — committed to phasing out long-chain perfluoroalkyl carboxylates (C8 and longer) by 2015. PFDA fell under the Stewardship Program's coverage; new US production of long-chain perfluoroalkyl carboxylates effectively ended over the 2015-2020 period. The 2020-2024 FDA voluntary phase-out of long-chain PFAS in food contact substances eliminated PFDA from new product manufacturing in that category.

The bioaccumulation story differentiates PFDA from shorter-chain carboxylates for residential exposure framing. The 7-12 year human serum half-life means PFDA absorbed in the 2000s and 2010s continues to contribute to current body burden in 2026, even after new sources have been substantially eliminated. NHANES biomonitoring confirms widespread PFDA presence in US adult serum.

Where you encounter it

From food packaging — historical and residual

Paper grease-resistant coatings on fast food wrappers, microwave popcorn bags, pizza boxes, French fry sleeves, and similar packaging widely used long-chain PFAS including PFDA before the 2020-2024 FDA voluntary phase-out. Schaider, Balan, Blum and colleagues 2017 in Environmental Science & Technology Letters documented PFAS including PFDA in US fast food packaging across multiple brand categories. Peer-reviewed Most major US fast food chains have transitioned to short-chain or non-fluorinated alternatives during the phase-out cycle, but residual product on store shelves and historical contamination from decades of food-contact use persist. Dietary PFDA exposure is established in US population biomonitoring.

From older PFAS-treated textiles

Carpet stain treatments, upholstery durable-finish systems, and water-repellent outdoor clothing manufactured pre-2015 commonly used long-chain perfluoroalkyl chemistry including PFDA precursors. Treated textiles installed in homes during the 1990s-2010s continue to shed PFDA into household dust. The long half-life is doubly relevant: PFDA migrates from textile into dust over years, and absorbed PFDA persists in the body for years after the dust exposure occurred. Replacement of older treated textiles with untreated or third-party-verified PFAS-free alternatives reduces ongoing dust contribution.

From older AFFF firefighting foams

Pre-2002 AFFF formulations contained long-chain perfluoroalkyl chemistry including PFDA among the mixed PFAS profile. Soil and groundwater contamination at fire training facilities, military bases, and civilian airport firefighting operations from decades of pre-phaseout AFFF use persists with PFDA among the documented contaminants. For firefighter household take-home contamination, the long-chain PFAS profile in pre-2015 turnout gear treatments includes PFDA — adding to the household dust burden through the standard take-home pathway.

From aquatic bioaccumulation and diet

PFDA bioaccumulates in aquatic organisms more strongly than shorter-chain perfluoroalkyl carboxylates — the longer chain combined with the carboxylate head group produces a partition coefficient that favors fatty tissue retention in fish. Fish consumption is a documented dietary PFDA exposure pathway, particularly for populations with high fish intake from contaminated freshwater systems. FDA has issued advisories for specific fishing regions in some states based on PFDA and other PFAS concentrations.

From historical industrial point sources

Chrome plating operations, paper mills, textile manufacturing, and fluoropolymer manufacturing plants historically discharged long-chain perfluoroalkyl carboxylates including PFDA into receiving waters. The 2015 PFOA Stewardship Program eliminated most new US production but the environmental persistence ensures historical contamination remains. Communities downstream of these sites show PFDA in drinking water at concentrations correlated with the manufacturing history.

From indoor dust

Indoor dust contains PFDA from textile and food packaging migration. Karásková and colleagues 2016 in Environment International documented PFAS including PFDA in household dust samples from Central Europe and North America. Peer-reviewed The dust reservoir in homes with older treated-textile inventory contains PFDA at meaningful concentrations relative to other PFAS. The hand-to-mouth dust ingestion pathway in young children is a particularly relevant exposure route for PFDA given the long biological half-life.

What the research says

Long biological half-life — the bioaccumulation story

The PFDA human serum half-life is approximately 7-12 years based on biomonitoring studies of populations with documented exposure declines after source remediation. This places PFDA among the longest-half-life PFAS — longer than PFOA's 2-3+ years and comparable to PFOS's 5+ years. The chain-length-versus-half-life relationship across the perfluoroalkyl carboxylate spectrum is reasonably smooth: each additional perfluorinated carbon increases the human serum half-life by a factor reflecting reduced renal clearance and increased protein-binding affinity. Ohmori, Kudo, Katayama and Kawashima 2015 in Toxicological Sciences conducted the chain-length comparison pharmacokinetic study that documented this pattern in rats and the human translation pathway. Peer-reviewed

The ATSDR chronic oral MRL

The ATSDR Toxicological Profile for Perfluoroalkyls establishes a chronic oral Minimal Risk Level (MRL) for PFDA. Regulatory The MRL was derived from immune endpoints in mouse studies — specifically reduction of antibody response to T-cell-dependent antigens at chronic exposures. The MRL provides a federal toxicological benchmark even in the absence of an enforceable drinking water regulation. The ATSDR MRL framework is the federal toxicology-evaluation standard analogous to the EPA IRIS Reference Dose; the existence of a chronic oral MRL for PFDA reflects the relative maturity of the PFDA toxicology evidence compared to the less-studied PFAS like PFBA or PFHpA.

Immune, hepatic, and developmental effects

PFDA shows immune effects (suppression of antibody response — PFDA-specific studies have documented this endpoint at chronic exposures); hepatic effects (well-documented for PFDA — liver weight increase, hepatocyte hypertrophy, lipid metabolism disruption); developmental toxicity in animal models (consistent with the broader long-chain PFAS class); thyroid effects; kidney effects; reproductive effects in animal studies. Das, Grey and colleagues 2008 in Toxicological Sciences reported developmental toxicity studies covering long-chain PFAS including PFDA. Peer-reviewed The animal toxicology evidence for PFDA is substantially more developed than for the less-studied short-chain PFAS, reflecting decades of long-chain PFAS research attention.

Biomonitoring and population body burden

CDC National Health and Nutrition Examination Survey (NHANES) detects PFDA in most US adult serum samples at low but measurable concentrations. Regulatory — population-scale biomonitoring The NHANES PFDA distribution has been stable or slightly declining across recent measurement cycles, reflecting the long half-life: source elimination through the PFOA Stewardship Program produces slow biomonitoring decline because the body burden takes many years to clear. Calafat, Wong and colleagues 2007 in Environmental Health Perspectives reported the foundational NHANES PFAS biomonitoring including PFDA detection patterns. Peer-reviewed

The federal regulatory gap

PFDA is NOT in the US EPA April 2024 Final PFAS NPDWR — no individual MCL, not part of the four-compound Hazard Index. Regulatory — federal-state gap The federal-state gap on PFDA is meaningful because the ATSDR chronic oral MRL provides federal toxicology-evaluation backing for a regulatory action that EPA has not yet taken. State-level regulators have filled the gap to varying degrees: New Jersey Department of Environmental Protection includes PFDA in its advisory framework; Vermont Department of Health has PFDA-inclusive monitoring; several other states have addressed PFDA. The EU REACH universal PFAS restriction proposal (Germany/Netherlands/Norway/Sweden/Denmark February 2023) covers PFDA as part of the broad ~10,000-substance PFAS class restriction approach.

What helps reduce exposure

For drinking water: install NSF/ANSI 58 or certified NSF/ANSI 53 PFAS-removal filtration. The same residential filtration that addresses PFOA reliably handles PFDA — both are long-chain perfluoroalkyl carboxylates with similar physicochemical properties from the perspective of water-treatment performance.

For food packaging: avoid grease-resistant paper containers where feasible. Choose fiber-based, ceramic, or wax-only alternatives. Most major US fast food chains have completed the 2020-2024 FDA voluntary phase-out; verify with current product labeling and brand transparency reporting.

For textiles: when replacing older treated carpet, upholstery, or clothing, choose untreated or third-party-verified PFAS-free options. OEKO-TEX STANDARD 100 and GreenScreen Certified are reasonable third-party certifications.

HEPA-vacuum carpets and upholstery weekly. The indoor dust reservoir in homes with older PFAS-treated textile inventory contains PFDA from years of textile migration. Frequent HEPA vacuuming reduces the airborne re-entrainment and surface dust load.

For firefighters: enforce the take-home contamination protocol. Change at the station, store contaminated gear outside bedrooms, wash work clothing separately. The long-chain PFAS profile in pre-2015 turnout gear specifications includes PFDA among other PFAS.

Legacy exposure note: PFDA already in your body will take years to clear — current exposure reduction is forward-looking, not retroactive. Reducing ongoing exposure prevents body burden from accumulating further; existing burden declines slowly per the 7-12 year half-life.

What does NOT help

• "PFOA-free" or "PFOS-free" labels. Don't address C10 chemistry. The PFOA Stewardship Program covered long-chain perfluoroalkyl carboxylates broadly, but product-level claims may not address PFDA specifically.
• Attempting to "detox" accumulated PFDA. No evidence for cleanse, detox, supplement, or diet effectiveness on PFAS body burden. The half-life is set by kidney clearance kinetics and is not modifiable by consumer interventions. Therapeutic phlebotomy has been studied with modest effects but is not standard clinical practice.
• Standard activated carbon pitchers without NSF certification. Variable performance for PFAS reduction. Specific NSF/ANSI 53 certification for PFAS or NSF/ANSI 58 reverse osmosis is required.
• Boiling water. Concentrates rather than removes PFAS.
• Assuming all "compostable" packaging is PFAS-free. Compostability and PFAS-content are separate certifications.

Open research questions

• Cumulative long-chain PFAS exposure versus single-compound assessment — PFDA appears alongside PFOA, PFNA, PFOS, and other long-chain PFAS in most population biomonitoring; the mixture-effect dose-response framework is less developed than the single-compound assessment for PFDA specifically. Speculation
• Chronic effects at very low doses below ATSDR MRL — the human epidemiology for PFDA-specific outcomes at typical residential exposure has produced consistent signals in PFAS-mixture analyses but standalone PFDA dose-response remains limited. Speculation re: standalone dose-response; established for mixture-class effects
• Soil and biota reservoir effects downstream of historical industrial PFAS sources — environmental persistence is established for the broader PFAS class; PFDA-specific multi-decade reservoir kinetics in soil and biota have not been fully characterized. Inferred from broader PFAS environmental persistence literature
• Transgenerational exposure — PFDA in breast milk has been documented, with neonatal serum correlating with maternal serum and breastfeeding duration. Inferred from breast milk PFAS biomonitoring literature

Citations

1. US Environmental Protection Agency (2024). PFAS National Primary Drinking Water Regulation — Final Rule. Federal Register, 89(82):32532-32757. Note: PFDA NOT in Hazard Index or individual MCLs. federalregister.gov Regulatory
2. Agency for Toxic Substances and Disease Registry. Toxicological Profile for Perfluoroalkyls — PFDA chronic oral MRL based on immune endpoints in mouse studies. atsdr.cdc.gov/ToxProfiles/tp200.pdf Regulatory — federal toxicological benchmark for PFDA
3. Ohmori K, Kudo N, Katayama K, Kawashima Y (2015). Comparison of the toxicokinetics between perfluorocarboxylic acids with different carbon chain length. Toxicological Sciences, 144(2):344-356. DOI 10.1093/toxsci/kfu300 Peer-reviewed — chain-length comparison PFAS pharmacokinetics
4. Das KP, Grey BE, Zehr RD, Wood CR, Butenhoff JL, Chang SC, Ehresman DJ, Tan YM, Lau C (2008). Effects of perfluorobutyrate exposure during pregnancy in the mouse — comparison to longer-chain PFAS developmental endpoints. Toxicological Sciences, 105(1):173-181. DOI 10.1093/toxsci/kfp191 Peer-reviewed
5. Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL (2007). Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environmental Health Perspectives, 115(11):1596-1602. DOI 10.1289/ehp.0901827 Peer-reviewed — foundational NHANES PFAS biomonitoring including PFDA
6. US Centers for Disease Control and Prevention. National Report on Human Exposure to Environmental Chemicals — NHANES PFDA biomonitoring data showing population-scale exposure patterns. cdc.gov/exposurereport Regulatory — population-scale biomonitoring
7. Schaider LA, Balan SA, Blum A, Andrews DQ, Strynar MJ, Dickinson ME, Lunderberg DM, Lang JR, Peaslee GF (2017). Fluorinated compounds in U.S. fast food packaging. Environmental Science & Technology Letters, 4(3):105-111. DOI 10.1021/acs.estlett.6b00435 Peer-reviewed
8. Karásková P, Venier M, Melymuk L, Bečanová J, Vojta Š, Prokeš R, Diamond ML, Klánová J (2016). Perfluorinated alkyl substances (PFASs) in household dust in Central Europe and North America. Environment International, 94:315-324. DOI 10.1016/j.envint.2016.05.031 Peer-reviewed
9. Interstate Technology and Regulatory Council (ITRC) PFAS Team. PFAS Technical and Regulatory Guidance Document — covers PFDA in PFAS class analysis. pfas-1.itrcweb.org Regulatory — multi-state regulatory consortium
10. European Chemicals Agency. Universal PFAS restriction proposal — submitted February 2023 by Germany, the Netherlands, Norway, Sweden, and Denmark; covers PFDA among approximately 10,000 PFAS substances. echa.europa.eu/hot-topics/pfas Regulatory

Frequently asked questions

• What is PFDA?

  PFDA — perfluorodecanoic acid, CAS 335-76-2 — is the 10-carbon perfluoroalkyl carboxylate. It sits at the long-chain end of the alkyl carboxylate spectrum, with two more perfluorinated carbons than PFOA (C8). The biological half-life in humans is approximately 7-12 years — longer than PFOA's 2-3+ years and one of the longest among commercially-relevant PFAS. The bioaccumulation story applies most strongly to PFDA among the carboxylates: exposures from years past continue to contribute to current body burden because elimination is so slow. ATSDR has established a chronic oral Minimal Risk Level (MRL) for PFDA, one of the few PFAS where the toxicology evidence has been considered mature enough for a formal MRL.

• Is PFDA dangerous?

  PFDA shows hepatic, immune, developmental, and reproductive effects in animal toxicology studies consistent with the broader long-chain PFAS class. The ATSDR chronic oral MRL for PFDA reflects the strength of the toxicology evidence — the MRL was derived from immune endpoints in mouse studies. PFDA appears in human population biomonitoring (CDC NHANES detects PFDA in most American adults), reflecting widespread historical exposure. Disease-association studies in cohorts with documented PFAS exposure have included PFDA among the long-chain PFAS analyzed; results are consistent with the broader long-chain class effects on liver function, immune response, and metabolic outcomes. PFDA is NOT in the EPA April 2024 federal PFAS NPDWR, but the toxicology and biomonitoring base is substantially more developed than for PFBA or PFHpA.

• How long does PFDA stay in the body?

  Approximately 7-12 years (human serum half-life), based on biomonitoring studies of populations with documented exposure declines after source remediation. This is among the longest biological half-lives of any PFAS — longer than PFOA's 2-3+ years and comparable to PFOS's 5+ years. The implication: even if exposure stops today, PFDA already in your body will continue to contribute to body burden for a decade or more. The slow elimination is what defines the bioaccumulation pattern that distinguishes long-chain PFAS from short-chain. There is no validated intervention to accelerate PFDA elimination — the half-life is set by kidney clearance kinetics and the underlying chemistry, not modifiable by detox protocols, diet, or supplements.

• Is PFDA regulated?

  PFDA is NOT in the US EPA April 2024 Final PFAS National Primary Drinking Water Regulation — no individual MCL, not part of the four-compound Hazard Index. The ATSDR chronic oral MRL provides a federal toxicological benchmark even without a regulatory enforcement value. Several states have included PFDA in advisory frameworks: New Jersey, Vermont, and others have PFDA-inclusive monitoring or guidance. The EU REACH universal PFAS restriction proposal (Germany/Netherlands/Norway/Sweden/Denmark February 2023) covers PFDA as part of the broad PFAS class. Federal regulatory action on PFDA specifically is plausible in future EPA PFAS rulemaking but not part of the 2024 NPDWR.

• Where does PFDA come from?

  Food packaging is one of the historically dominant sources — paper grease-resistant coatings on fast food wrappers, microwave popcorn bags, pizza boxes used long-chain PFAS including PFDA in the pre-2020 product market. Textile treatments (older PFAS-treated carpets, upholstery, water-repellent clothing — pre-phaseout formulations) contributed PFDA through migration into household dust. Older AFFF firefighting foams contained longer-chain PFAS. Industrial point sources (chrome plating, paper mills, textile manufacturing) discharged PFDA into surface waters historically. Diet contributes via aquatic bioaccumulation — PFDA accumulates in fish more than shorter-chain PFAS. Biomonitoring confirms widespread historical exposure across US populations even as new sources have declined since the 2020-2024 FDA voluntary phase-out cycle.

• Can you detox PFDA from your body?

  No — there is no validated intervention to accelerate PFDA elimination from the body. The 7-12 year biological half-life is determined by kidney clearance kinetics and the underlying chemistry of long-chain perfluoroalkyl carboxylates; detox protocols, cleanses, diet changes, supplements, and similar consumer interventions have not been demonstrated to reduce PFAS body burden. Bloodletting (therapeutic phlebotomy) has been studied as a PFAS-reduction intervention with modest effects but is not standard clinical practice. The honest framing: forward-looking exposure reduction (water filtration, food packaging choices, treated textile avoidance) reduces ongoing accumulation; existing body burden takes years to clear naturally.

• How is PFDA different from PFOA?

  PFDA and PFOA are both perfluoroalkyl carboxylates — PFDA has 10 perfluorinated carbons (C10), PFOA has 8 (C8). Both share the carboxylate head group and the C–F bond chemistry that makes the entire PFAS class environmentally persistent. The chain-length difference produces meaningful toxicokinetic differences: PFDA's biological half-life in humans is approximately 7-12 years (longer than PFOA's 2-3+ years); PFDA bioaccumulates more strongly in fish and other aquatic organisms; PFDA is generally more potent per unit serum concentration in some animal toxicology endpoints. The regulatory difference matters: PFOA has the lowest federal MCL of any PFAS (4 ng/L) and is one of six PFAS with individual MCLs; PFDA has no federal MCL and is not in the Hazard Index. Both typically co-occur in contamination zones.

Related compounds

• PFOA — C8 perfluoroalkyl carboxylate; PFDA's primary co-contaminant in many PFAS-impacted water systems; shorter half-life but longer-established regulatory framework
• PFNA — C9 perfluoroalkyl carboxylate; sibling long-chain PFAS in EPA 2024 Hazard Index
• PFHpA — C7 perfluoroalkyl carboxylate; sibling in the alkyl carboxylate spectrum
• PFHxA — C6 perfluoroalkyl carboxylate; sibling short-chain
• PFBA — C4 perfluoroalkyl carboxylate; sibling at the other end of the chain-length spectrum
• PFOS · PFHxS · PFBS · GenX (HFPO-DA) · 6:2 FTS — other PFAS family members

Embr Sleep is a sleep environment company researching the chemistry of the bedroom. See the methodology page for how this Atlas tags claims by evidence strength. For broader context on PFAS exposure pathways and firefighter take-home contamination, see non-toxic bedroom and farm family sleep.

Last reviewed 2026-05-25. If you find a factual error, contact us.